Clinical Trial Search

Primary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event

Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners

Primary: Doxycycline Concentrations in Rectal Tissues — 0.863; 2.193 µg/g

Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants

Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants

Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g

Primary: Efficacy of Internet-based Program for Increasing Condom Use With Non-main Sex Partners — .68; .56 percentage of sex acts protected by cond

Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT

Primary: Incidence of N. Gonorrhoeae, C. Trachomatis, or Early Syphilis Infection by Laboratory-based Diagnosis — 25.1; 29.0 Events per 100 person-years

Primary: STI Incidence — 250; 226 participants

Primary: Rectal Doxycycline Concentration — 0.654 µg/g

Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04

Primary: HPV Prevalence — 61 participants

Primary: Incidence Rate of Ng Plus Ct Detected at Any Site Whilst Individuals Are Screened vs. Not Screened — 0.155; 0.205 Ng or CT cases per study visit

Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05

Primary: Number of Subjects Who Had New Sexual Relationships — 56; 37; 61 Participants

Primary: Syphilis Tests Undertaken — 29; 37 Participants

Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants

Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Mean Number of Doses of HBV Vaccine Received — .78; .85; .94; .98 Doses of HBV Vaccine — p==.885

Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000

Primary: Proportion of Participants Who Did Not Complete the 28-day PEP Regimen — 114 Participants

Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…

Primary: Self-reported HIV or STI Testing in Past 3 Months — 76; 88 Participants — p=0.914

Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants

Primary: Sex Risk Behaviors: Number of Sex Partners (>=2 Sex Partners) — 17; 29; 50; 53 participants — p=<0.01

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants

Primary: Number of Participants With Risky Sexual Behavior Measured for 1 Year — 143; 155; 162 Participants